Ocugen, Inc. Profile Avatar - Palmy Investing

Ocugen, Inc.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function…

Biotechnology
US, Malvern [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of OCGN's Analysis
CIK: 1372299 CUSIP: 67577C105 ISIN: US67577C1053 LEI: - UEI: -
Secondary Listings
OCGN has no secondary listings inside our databases.